Trevi Therapeutics financials
$14.40−0.07%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$20.5M | -$14.9M | -$10.2M | -$13.9M | -$13.7M | -$11.5M | -$12.2M | -$14.1M | -$13.3M | -$11.9M | -$8.9M | -$9.0M |
| Net income | -$17.8M | -$13.2M | -$8.3M | -$11.8M | -$12.3M | -$10.3M | -$11.4M | -$13.2M | -$12.4M | -$10.9M | -$7.8M | -$7.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.11 | $-0.09 | $-0.06 | $-0.08 | $-0.09 | $-0.09 | $-0.11 | $-0.13 | $-0.12 | $-0.11 | $-0.08 | $-0.08 |
| EBITDA | -$20.5M | -$14.9M | -$10.2M | -$13.9M | -$13.7M | -$11.4M | -$12.2M | -$14.1M | -$13.3M | -$11.9M | -$8.9M | -$9.0M |
| Operating cash flow | -$17.4M | -$16.7M | -$7.6M | -$10.9M | -$10.1M | -$13.5M | -$9.6M | -$9.6M | -$8.7M | -$10.5M | -$6.4M | -$7.3M |
| Free cash flow | -$17.6M | -$16.8M | -$7.6M | -$10.9M | -$10.1M | -$13.5M | -$9.6M | -$9.6M | -$8.7M | -$10.5M | -$6.4M | -$7.3M |
| Diluted shares | 156.6M | 145.6M | 145.9M | 145.1M | 130.4M | 117.6M | 106.0M | 101.3M | 101.0M | 99.5M | 99.5M | 99.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $54.3M | $19.4M | $18.9M | $56.9M | $117.1M | $19.4M |
| Short-term investments | $264.6M | $152.4M | $169.3M | $138.1M | $86.8M | $83.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $330.5M | $179.6M | $193.4M | $199.4M | $208.3M | $107.0M |
| Total liabilities | $9.0M | $7.5M | $10.2M | $9.6M | $9.8M | $7.5M |
| Shareholders' equity | $321.5M | $172.1M | $183.2M | $189.8M | $198.5M | $99.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology